ACCD Stock Recent News
ACCD LATEST HEADLINES
Accolade (ACCD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Accolade, Inc. (NASDAQ:ACCD ) Q2 2025 Earnings Conference Call October 8, 2024 8:00 AM ET Company Participants Todd Friedman - Senior Vice President of Investor Relations Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Conference Call Participants Dan Clark - Leerink Partners Craig Hettenbach - Morgan Stanley Jailendra Singh - Truist Securities Jeff Garro - Stephens Inc. Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Jared Haase - William Blair Stephanie Davis - Barclays Allen Lutz - Bank of America Ryan MacDonald - Needham & Company Stan Berenshteyn - Wells Fargo David Larsen - BTIG Jack Wallace - Guggenheim Operator Ladies and gentlemen, thank you for standing by. Welcome to Accolade Second Quarter 2025 Earnings Results Conference Call.
On October 8, 2024, Accolade Inc (ACCD, Financial) released its 8-K filing detailing the financial results for the fiscal second quarter ending August 31, 2024. Accolade Inc, a company offering technology-enabled solutions to navigate the healthcare system, reported a revenue of $106.4 million, exceeding the analyst estimate of $105.01 million.
SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024.
SEATTLE, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will release fiscal second quarter 2025 financial results on Tuesday, October 8, 2024 before market open. In conjunction, the company will host a conference call to review results at 8:00 a.m. E.T. on the same day.
Accolade (ACCD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.
SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference in New York on Thursday, September 5 at 9:15 am ET.
NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.
NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Accolade, Inc. ("Accolade") (NASDAQ:ACCD) concerning possible violations of federal securities laws. On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share.